Cargando…

Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer

BACKGROUND: MammaPrint® is a microarray-based gene expression test cleared by the US Food and Drug Administration to assess recurrence risk in early-stage breast cancer, aimed to guide physicians in making neoadjuvant and adjuvant treatment decisions. The increase in the incidence of invasive lobula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beumer, Inès J., Persoon, Marion, Witteveen, Anke, Dreezen, Christa, Chin, Suet-Feung, Sammut, Stephen-John, Snel, Mireille, Caldas, Carlos, Linn, Sabine, van ’t Veer, Laura J., Bernards, Rene, Glas, Annuska M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153320/ https://www.ncbi.nlm.nih.gov/pubmed/27980389 http://dx.doi.org/10.4137/BMI.S38435

Ejemplares similares

Equivalence of MammaPrint array types in clinical trials and diagnostics
por: Beumer, Inès, et al.
Publicado: (2016)

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
por: Haan, Josien C., et al.
Publicado: (2021)

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris
por: Slembrouck, Laurence, et al.
Publicado: (2019)

A breast cancer gene signature for indolent disease
por: Delahaye, Leonie J. M. J., et al.
Publicado: (2017)

Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer
por: Tian, Sun, et al.
Publicado: (2010)

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017)

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
por: Soliman, Hatem, et al.
Publicado: (2020)

MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
por: Espinel, C. Francisco, et al.
Publicado: (2012)

Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients
por: Fatima, Areej, et al.
Publicado: (2017)

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
por: Dubsky, P., et al.
Publicado: (2020)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Myburgh, Ettienne J., et al.
Publicado: (2021)

Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint
por: Amezcua-Gálvez, Jesús Eduardo, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
por: Wuerstlein, R., et al.
Publicado: (2019)

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
por: Whitworth, Pat, et al.
Publicado: (2014)

A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Lee, Young Joo, et al.
Publicado: (2021)

RE: The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Mansani, Fabio Postiglione, et al.
Publicado: (2022)

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
por: Mittempergher, Lorenza, et al.
Publicado: (2020)

A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers
por: In’t Veld, Sjors G. J. G., et al.
Publicado: (2017)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
por: Bösl, Andreas, et al.
Publicado: (2017)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests
por: Jahn, Stephan Wenzel, et al.
Publicado: (2020)

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Hwang, Young Sol, et al.
Publicado: (2022)

A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction
por: Yao, Kevin, et al.
Publicado: (2022)

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing
por: Bai, Qianming, et al.
Publicado: (2023)

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Blumencranz, Peter, et al.
Publicado: (2023)

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
por: Pan, Bo, et al.
Publicado: (2023)

Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial
por: Jacob, Laurent, et al.
Publicado: (2020)

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
por: Severson, Tesa M., et al.
Publicado: (2017)

A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility
por: Roepman, Paul, et al.
Publicado: (2009)

Converting a breast cancer microarray signature into a high-throughput diagnostic test
por: Glas, Annuska M, et al.
Publicado: (2006)

Mamma Roma
por: Pasolini, Pier Paolo, 1922-1975
Publicado: (1965)

Mamma Succenturiata
por: Duncan, Matthews
Publicado: (1873)

Undeveloped Mammæ
por: Mask, W. B.
Publicado: (1894)

Mamma [popular Italian songs /
Publicado: (1984)

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer
por: Michaut, Magali, et al.
Publicado: (2016)

Sarcoma of Female Mamma
por: Beatson, George Thomas
Publicado: (1909)

Hypertrophy of the Female Mamma
por: Beatson, George Thomas
Publicado: (1908)

Notes on Excision of the Mamma
por: Bell, Joseph
Publicado: (1871)

Cannot write session to /tmp/vufind_sessions/sess_omr9vogrvlpog97jhhla6gtom9